23 January 2020
New York/London, 23 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces the Company has today filed a Form...
Read more21 January 2020
New York/London, 21 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, is pleased to announce appointment of Mr. Gregor...
Read more14 January 2020
New York/London, 14 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 13 January 2020 it...
Read moreOur mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases, autoimmune and inflammatory diseases and optimizing health outcomes.
Learn moreWith several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.
Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.
Learn more about MilciclibForalumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of NASH, Crohn’ s Disease and a neurodegenerative indication.
Learn more about ForalumabWith several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.
Learn more about Anti IL-6rStemPrintER is a multi-gene signature assay intended for use as a diagnostic screen in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.
Learn more about StemPrintER™Tiziana is currently conducting clinical development programs for Foralumab and Milciclib
We initiated a Phase 2a trial (CDKO-125a-010) of Milciclib safety and tolerability as a single therapy in sorafenib-resistant patients with HCC in the first half of 2017.
See more Milciclib clinical trialsTiziana is currently conducting a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston.
See more Foralumab clinical trials
